drugset / Trial / NCT07174063
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.
Timeline
- Start
- 2025-11-26
- Primary completion
- 2027-01-29
- Completion
- 2027-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luxdegalutamide | Small molecule | 100 mg | Oral |
| Subject | Luxdegalutamide | Small molecule | 300 mg | Oral |